Fig. 7

Impact of chronic severe thrombocytopenia on proliferation and apoptosis in B16F1 and AT-3 tumors. (A) Schematic representation of severe chronic thrombocytopenia induction. Starting from the day of B16F1 and AT-3 tumor cell implantation, c-mpl-deficient mice were injected every 5 days with a platelet-depleting polyclonal antibody at low dose (0.5 µg/g mouse). Littermate control mice were injected with a non-immune IgG. (B) Wet weight of B16F1 tumors (platelet 100%, n = 27; <10%, n = 24) and AT-3 tumors (platelet 100%, n = 28; <10%, n = 32). (C) Quantification of KI67-positive cells in B16F1 tumors and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia. n = 7 (100%) and 9 (< 10%) different B16F1 tumors; and n = 7 (100%) and 8 (< 10%) different AT-3 tumors. (D) Quantification of TUNEL-positive cells in B16F1 tumors and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia mice. n = 7 (100%) and 9 (< 10%) different B16F1 tumors; and n = 5 (100%) and 7 (< 10%) different AT-3 tumors. ns: non-significant